Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer : a phase 2 adaptive trial

Immune checkpoint inhibition (ICI) with chemotherapy is now the standard of care for stage II-III triple-negative breast cancer; however, it is largely unknown for which patients ICI without chemotherapy could be an option and what the benefit of combination ICI could be. The adaptive BELLINI trial...

Ausführliche Beschreibung

Bibliographische Detailangaben

Hauptverfasser:	Nederlof, Iris, Isaeva, Olga I, de Graaf, Manon, Gielen, Robbert C. A. M, Bakker, Noor A. M, Rolfes, Adrianne L, Garner, Hannah, Boeckx, Bram, Traets, Joleen J. H, Mandjes, Ingrid A. M, de Maaker, Michiel, van Brussel, Thomas, Chelushkin, Maksim, Champanhet, Elisa, Lopez-Yurda, Marta, Van de Vijver, Koen, van den Berg, Jose G, Hofland, Ingrid, Klioueva, Natasja, Mann, Ritse M, Loo, Claudette E, van Duijnhoven, Frederieke H, Skinner, Victoria, Luykx, Sylvia, Kerver, Emile, Kalashnikova, Ekaterina, van Dongen, Marloes G. J, Sonke, Gabe S, Linn, Sabine C, Blank, Christian U, de Visser, Karin E, Salgado, Roberto, Wessels, Lodewyk F. A, Drukker, Caroline A, Schumacher, Ton N, Horlings, Hugo M, Lambrechts, Diether, Kok, Marleen
Format:	Artikel
Sprache:	eng
Schlagworte:	ANTI-CTLA-4 BLOCKADE CRITERIA EFFICACY EVENT-FREE SURVIVAL IMMUNOTHERAPY Medicine and Health Sciences PEMBROLIZUMAB PROGNOSTIC VALUE T-CELLS TUMOR-INFILTRATING LYMPHOCYTES
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!